Since several PRMT5 inhibitors are under preclinical and clinical studies for the treatment of cancer (58), our results suggest that PRMT5 inhibitors may have other therapeutic implications in human diseases, such as diabetic retinopathy, macular degeneration, and diabetic nephropathy. This evidence concerns the gene PRMT5 and macular degeneration.